Monitoring for adverse effects from systemic drugs used in dermatology

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of 'risk-risk' assessment and 'critical toxicities' are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.

Original languageEnglish (US)
Pages (from-to)661-679
Number of pages19
JournalJournal of the American Academy of Dermatology
Volume26
Issue number5 I
StatePublished - 1992

Fingerprint

Dermatology
Pharmaceutical Preparations
Patient Participation
Dapsone
Retinoids
Skin Diseases
Methotrexate
Cyclosporine
Signs and Symptoms
Habits
Early Diagnosis
Adrenal Cortex Hormones
Guidelines
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

Monitoring for adverse effects from systemic drugs used in dermatology. / Wolverton, Stephen.

In: Journal of the American Academy of Dermatology, Vol. 26, No. 5 I, 1992, p. 661-679.

Research output: Contribution to journalArticle

@article{d0d0a1b0a42542dfb604295f108fedee,
title = "Monitoring for adverse effects from systemic drugs used in dermatology",
abstract = "Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of 'risk-risk' assessment and 'critical toxicities' are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.",
author = "Stephen Wolverton",
year = "1992",
language = "English (US)",
volume = "26",
pages = "661--679",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5 I",

}

TY - JOUR

T1 - Monitoring for adverse effects from systemic drugs used in dermatology

AU - Wolverton, Stephen

PY - 1992

Y1 - 1992

N2 - Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of 'risk-risk' assessment and 'critical toxicities' are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.

AB - Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of 'risk-risk' assessment and 'critical toxicities' are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.

UR - http://www.scopus.com/inward/record.url?scp=0026653747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026653747&partnerID=8YFLogxK

M3 - Article

C2 - 1583165

AN - SCOPUS:0026653747

VL - 26

SP - 661

EP - 679

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5 I

ER -